

MFM Neo Clinical Trials Workshop Information Aspen Colorado, August 2010

At the Aspen meeting, there is a Clinical trials workshop. In this activity, we will be discussing and designing a clinical trial. Prior to the workshop there will be a presentation on the topic to set the stage. In addition, the questions below will help you to prepare for the workshop – you will be expected to have reviewed this material and the suggested reading to actively participate in the workshop.

Questions to help you prepare for the Aspen Clinical Trial design Workshop: *Use of Antenatal Steroids to Improve Outcomes in the Late Preterm gestation*

1. What is the quality of evidence for each of the following*
 - Antenatal corticosteroids (ACS) administered at 24-34 weeks gestation reduce the neonatal complications in infants born within 7 days of administration
 - ACS administered at 24-34 weeks gestation reduce the neonatal complications in infants born after 7 days of administration
 - Multiple courses of ACS in a pregnancy are safe and have no adverse outcomes or long term implications for the neonate/infant/child
 - ACS administered at 34-37 weeks gestation reduce the neonatal complications in infants born within 7 days of administration
 - The available data demonstrates that a single course of ACS administered at 34-37 weeks gestation is safe for the fetus and mother
 - ACS can and should be used in the management of patients at risk for late preterm delivery
2. Before doing a RCT on the use of ACS in the late preterm period, is there a need for (a) descriptive epidemiology (b) observational study to determine if there are associated morbidities and assess the effectiveness and safety of treatment? Are these studies possible?
3. In an investigative design, what treatment regimens should/can be compared?
4. **Masking:** Should/can the treatment groups be masked or "blinded"? How could this be accomplished?
5. **Primary outcome:**
 - a) Should this be efficacy or safety of the treatment? Which outcome (s) should be included as clinically significant measures? How do you specify the outcome measure(s)?
 - b) Which perinatal outcome(s) are of secondary importance, but worthwhile collecting data on?
 - c) Are there any long-term effects that should be measured in the infants/mothers exposed in this protocol?
6. **"Study condition":** This is the population with the "condition of interest". What would be the ideal study condition to test?
7. **Study population:** a) What group of patients would you screen to obtain the study population? b) What would your inclusion and exclusion criteria be?

*Quality of Evidence:

- I. One RCT
- II. Controlled Trials / No randomization
 - cohort (case control studies)
 - multiple time series / dramatic effect
- III. Opinion of experts / descriptive studies, expert committees

8. What proportion of women with the condition would be ineligible by the criteria?
9. Are there any subgroups that should be focused on for analysis (age, race, ethnicity, parity, multiple gestation, etc)? What is the effect of subgroup analysis on study design?
10. To what extent would you "standardize" the clinical managements of the randomized patients?
11. If a well-designed RCT showed no difference between groups, how would you explain these results?
12. **Sample Size** (will be discussed at the meeting)
 - a) Prevalence of primary outcome: How would you go about estimating the frequency of the primary outcome in this population?
 - b) Effect size: How much more effective should treatment be than non-treatment in terms the primary outcome?
13. **Feasibility** (will be discussed at the meeting)
 - a) Study sample: What proportion of the eligible pool would reasonably consent to be randomized in a RCT?
 - b) How many pregnancies would be required to recruit the required sample?
14. Compliance with protocol and Protocol violations: how important is compliance with the protocol? What effect does protocol violations, withdrawals or loss to follow up have on the interpretation of the results? Would you exclude patients with protocol violations or who withdraw?

Suggested Reading

- American College of Obstetricians and Gynecologists. Antenatal Corticosteroid therapy for fetal maturation. Committee Opinion Number 273, May 2002.
- Ananth CV, Gyamfi C, Jain L. Characterizing risk profiles of infants who are delivered at late preterm gestations: does it matter? *Am J Obstet Gynecol*. 2008 Oct;199(4):329-31.
- Angus DC, Linde-Zwirble WT, Clermont G, et al. Epidemiology of neonatal respiratory failure in the United States: projections from California and New York. *Am J Respir Crit Care Med* 164:1154-60, 2001.
- Aziz K, Barrington KJ, Embree J, et al. Guidelines for detection, management and prevention of hyperbilirubinemia in term and late preterm newborn infants (35 or more weeks' gestation) - Summary. *Paediatrics & Child Health*. 2007;12(5):401-407.
- Chyi LJ, Lee HC, Hintz SR, Gould JB, Sutcliffe TL. School outcomes of late preterm infants: special needs and challenges for infants born at 32 to 36 weeks gestation. *J Pediatr*. 2008;153(1):25-31.
- Clark RH. The epidemiology of respiratory failure in neonates born at an estimated gestational age of 34 weeks or more. *J Perinatol* 25(4):251-7, 2005.
- Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal steroid administration on the infant: Long-term follow-up. *J Pediatr* 104:259-267, 1984.
- Crowley P, Chalmers, I, Keirse MFNC. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. *Br J Obstet Gynaecol* 97:11-25, 1990.
- Davidoff MJ, Dias T, Damus K, et al. Changes in the gestational age distribution among US singleton births: Impact on rates of late preterm birth, 1992 to 2002. *Semin Perinatol* 30:8-15, 2006.
- Dudell GG, Jain L. Hypoxic respiratory failure in the late preterm infant. *Clin Perinatol* 33:803-30, 2006.
- Engle WA, Kominiarek MA. Late preterm infants, early term infants, and timing of elective deliveries. *Clinics in Perinatology*. 2008;35(2):325-+.
- Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. *Pediatrics*. Feb 2008;121(2):419-432.
- Escobar GJ, Clark RH, Greene JD. Short-term outcomes of infants born at 35 and 36 weeks gestation: we need to ask more questions. *Semin Perinatol* 30:28-33, 2006.
- Gilbert WM, Nesbitt TS, Danielson B. The cost of prematurity: quantification by gestational age. *Obstet Gynecol* 102:488-492, 2003.
- Hamilton BE, Martin JA, SJ. V. Births: Preliminary data for 2007. In: Services DoHaH, ed. National Vital statistics Reports. Vol 57; 2009:1-23.
- Hankins GDV. "Late-Preterm" infants: A population at risk (vol 120. pg 1390, 2007). *Pediatrics*. 2008;121:451-451.
- Jain L, Chen XJ, Ramosevac S, Brown LA, Eaton DC. Expression of highly selective sodium channels in alveolar type II cells is determined by culture conditions. *Am J Physiol Lung Cell mol Physiol* 280:L646-58, 2001.
- Jain L. Morbidity and Mortality in Late-Preterm Infants: More than Just Transient Tachypnea! *Journal of Pediatrics* Volume 151, Issue 5, November 2007, Pages 445-446
- Jain L. Respiratory morbidity in late-preterm infants: Prevention is better than cure! *American Journal of Perinatology*. 2008;25:75-78.
- Kramer M, Hogue C. Inter- and intra-racial variation in very preterm birth rates across 300 US cities. *American Journal of Epidemiology*. 2008;167(11):S140-S140.
- Kramer MS, Demissie K, Yang H, et al. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System 284(7):843-9, 2000.
- Lupton A, Jackson DL. Cold stress and hypoglycemia in the late preterm ("near-term") infant: impact on nursery of admission. *Semin Perinatol* 30:77-80, 2006.
- Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. *Pediatrics* 50:515-525, 1972.
- Neu J. Gastrointestinal maturation and feeding. *Semin Perinatol* 30(1):24-7, 2006.

- NIH Consensus Development Panel. Effect of corticosteroids for fetal maturation on perinatal outcomes. *JAMA* 273:413-418.
- Raju TN, Higgins RD, Stark AR, et al. Optimizing care and outcome for late preterm (near-term) infants, a summary of the workshop sponsored by the National institute of Child Health and Human Development. *Pediatrics* 118(3):1207-14, 2006.
- Raju TNK. Late-preterm births: Challenges and opportunities. *Pediatrics*. 2008;121:402-403.
- Reddy UM, Ko CW, Raju TN, Willinger M. Delivery indications at late-preterm gestations infant mortality rates in the United States. *Pediatrics*. Jul 2009;124(1):234-240.
- Shapiro-Mendoza CK, Tomashel KM, Kotelchuck M, et al. Risk factors for neonatal morbidity and mortality among "healthy", late preterm infants. *Semin Perinatol* 30:55-60, 2006.
- Smolders-deHaas H, Neuvel J, Schmand B, et al. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: A 10-12 year follow-up. *Pediatrics* 86:65-70, 1990.
- Stutchfield P, Whitaker R, Russell I. Antenatal betamethasone and incidence of neonatal respiratory distress after elective cesarean section: pragmatic randomized trial. *Brit Med J* 331(7518):662. Epub Aug 22, 2005.
- Taylor HG, Espy KA, Anderson PJ. Mathematics deficiencies in children with very low birth weight or very preterm birth. *Dev Disabil Res Rev*. 2009;15(1):52-59.
- Tomashek KM, Shapiro-Mendoza CK, Weiss J, et al. Risk factors for neonatal morbidity and mortality among "health", late preterm infants. *Semin Perinatol* 30:61-68, 2006.
- Ventolini G, Neiger R, Mathews L, Adragna N, Belcastro M. Incidence of respiratory disorders in neonates born between 34 and 36 weeks of gestation following exposure to antenatal corticosteroids between 24 and 34 weeks of gestation. *Am J Perinatol*. Feb 2008;25(2):79-83.
- Wang ML, Dorer DJ, Fleming MP, et al. Clinical outcomes of near-term infants. *Pediatrics* 114(2):372-6, 2004.
- Williamson DM, Abe K, Bean C, Ferre C, Henderson Z, Lackritz E. Current research in preterm birth. *J Womens Health (Larchmt)*. Dec 2008;17(10):1545-1549.
- Yoder BA, Gordon MC, Barth WH. Late-preterm birth - Does the changing obstetric paradigm alter the epidemiology of respiratory complications? *Obstetrics and Gynecology*. 2008;111(4):814-822.
- Young PC, Glasgow TS, Li X, Guest-Warnick G, Stoddard G. Mortality of late-preterm (near-term) newborns in Utah. *Pediatrics*. Mar 2007;119(3):e659-665.